Total Payments
$172,778
2024 Payments
$901.17
Companies
71
Transactions
745
Medicare Patients
8,079
Medicare Billing
$1.3M
Payment Breakdown by Category
Research$145,091 (84.0%)
Food & Beverage$12,286 (7.1%)
Consulting$8,358 (4.8%)
Other$5,754 (3.3%)
Travel$1,051 (0.6%)
Education$237.80 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $145,091 | 18 | 84.0% |
| Food and Beverage | $12,286 | 679 | 7.1% |
| Consulting Fee | $8,358 | 18 | 4.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,004 | 18 | 2.3% |
| Honoraria | $1,750 | 1 | 1.0% |
| Travel and Lodging | $1,051 | 4 | 0.6% |
| Education | $237.80 | 7 | 0.1% |
Payments by Type
Research
$145,091
18 transactions
General
$27,687
727 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $106,959 | 9 | $0 (2023) |
| ACADIA Pharmaceuticals Inc | $42,876 | 79 | $0 (2024) |
| Allergan, Inc. | $3,082 | 54 | $0 (2021) |
| CATALYST PHARMACEUTICALS, INC. | $1,772 | 2 | $0 (2021) |
| Eisai Inc. | $1,704 | 3 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $1,363 | 50 | $0 (2024) |
| GENZYME CORPORATION | $1,346 | 54 | $0 (2023) |
| ABBVIE INC. | $1,252 | 52 | $0 (2024) |
| BIOTRONIK INC. | $939.59 | 7 | $0 (2022) |
| Biogen, Inc. | $909.69 | 15 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $901.17 | 38 | ABBVIE INC. ($192.87) |
| 2023 | $2,963 | 44 | Eli Lilly and Company ($1,360) |
| 2022 | $11,880 | 116 | ACADIA Pharmaceuticals Inc ($4,916) |
| 2021 | $92,208 | 112 | Eli Lilly and Company ($85,470) |
| 2020 | $36,077 | 81 | Eli Lilly and Company ($16,805) |
| 2019 | $24,307 | 162 | ACADIA Pharmaceuticals Inc ($21,134) |
| 2018 | $2,026 | 97 | Teva Pharmaceuticals USA, Inc. ($192.30) |
| 2017 | $2,416 | 95 | Dr.Reddy's Laboratories,Inc. ($417.00) |
All Payment Transactions
745 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: Neuroscience | ||||||
| 12/18/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $27.67 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 12/13/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/11/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $24.29 | General |
| Category: PAIN | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $17.78 | General |
| Category: Neuroscience | ||||||
| 12/04/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $29.92 | General |
| Category: Neurology | ||||||
| 12/04/2024 | MDD US Operations, LLC | Apokyn (Drug) | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: APOMORPHINE HYDROCHLORIDE | ||||||
| 11/20/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $22.32 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 11/13/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological), INBRIJA | Food and Beverage | In-kind items and services | $21.18 | General |
| Category: Musculoskeletal | ||||||
| 11/06/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $22.56 | General |
| Category: Neuropsychiatry | ||||||
| 11/01/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $32.91 | General |
| Category: Neurology | ||||||
| 10/30/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $30.20 | General |
| Category: Immunology | ||||||
| 10/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $27.07 | General |
| Category: IMMUNOLOGY | ||||||
| 10/23/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $24.99 | General |
| 10/18/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $22.83 | General |
| Category: Rare Disease | ||||||
| 10/15/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $31.29 | General |
| Category: NEUROSCIENCE | ||||||
| 10/02/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $21.32 | General |
| Category: Neuroscience | ||||||
| 09/10/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $24.56 | General |
| Category: Neurology | ||||||
| 09/05/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $33.74 | General |
| Category: NEUROSCIENCE | ||||||
| 09/04/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $24.35 | General |
| Category: Immunology | ||||||
| 08/30/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $20.48 | General |
| Category: Neuroscience | ||||||
| 08/29/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $24.15 | General |
| 08/28/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $28.53 | General |
| Category: PAIN | ||||||
| 08/21/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $13.12 | General |
| Category: NEUROSCIENCE | ||||||
| 07/30/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | RADICAVA (Drug), RADICAVA ORS | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: AMYOTROPHIC LATERAL SCLEROSIS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $54,026 | 3 |
| PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | Eli Lilly and Company | $48,856 | 2 |
| ACA 16-cAC-0001 | ACADIA Pharmaceuticals Inc | $37,500 | 6 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $2,697 | 1 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $1,005 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUTERATED [D6]-DEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $632.10 | 3 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $355.00 | 1 |
| A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | Eli Lilly and Company | $20.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 1,906 | 8,798 | $1.6M | $382,186 |
| 2022 | 10 | 1,858 | 2,555 | $1.3M | $302,309 |
| 2021 | 13 | 2,142 | 2,942 | $1.2M | $310,807 |
| 2020 | 14 | 2,173 | 2,787 | $1.0M | $269,828 |
Total Patients
8,079
Total Services
17,082
Medicare Billing
$1.3M
Procedure Codes
60
All Medicare Procedures & Services
60 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 932 | 1,609 | $674,863 | $154,559 | 22.9% |
| J3032 | Injection, eptinezumab-jjmr, 1 mg | Office | 2023 | 11 | 6,100 | $281,820 | $82,411 | 29.2% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2023 | 79 | 88 | $125,899 | $30,705 | 24.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 240 | 240 | $132,804 | $30,654 | 23.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 153 | 170 | $101,082 | $23,673 | 23.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 188 | 250 | $74,483 | $15,979 | 21.5% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 50 | 51 | $62,234 | $15,478 | 24.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 73 | 73 | $53,462 | $12,382 | 23.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 55 | 74 | $15,893 | $4,627 | 29.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 31 | 31 | $12,680 | $3,298 | 26.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 19 | 19 | $11,361 | $2,554 | 22.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 21 | 21 | $7,792 | $1,658 | 21.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 16 | $4,935 | $1,558 | 31.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 11 | 28 | $6,068 | $1,444 | 23.8% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 28 | 28 | $5,238 | $1,207 | 23.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 871 | 1,480 | $620,972 | $145,131 | 23.4% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2022 | 119 | 121 | $173,148 | $43,725 | 25.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 302 | 302 | $167,117 | $37,661 | 22.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 133 | 140 | $83,247 | $20,362 | 24.5% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2022 | 50 | 51 | $62,216 | $15,678 | 25.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 162 | 206 | $61,380 | $14,013 | 22.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 69 | 69 | $50,533 | $12,266 | 24.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 68 | 102 | $21,907 | $5,918 | 27.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 41 | 41 | $16,770 | $4,593 | 27.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 26 | 26 | $9,646 | $2,172 | 22.5% |
About Dr. Marc Feinberg, M.D
Dr. Marc Feinberg, M.D is a Specialist healthcare provider based in Boca Raton, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255422127.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marc Feinberg, M.D has received a total of $172,778 in payments from pharmaceutical and medical device companies, with $901.17 received in 2024. These payments were reported across 745 transactions from 71 companies. The most common payment nature is "" ($145,091).
As a Medicare-enrolled provider, Feinberg has provided services to 8,079 Medicare beneficiaries, totaling 17,082 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 60 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Boca Raton, FL
- Active Since 09/27/2006
- Last Updated 11/17/2016
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1255422127
Products in Payments
- NUPLAZID (Drug) $42,876
- UBRELVY (Drug) $3,478
- FIRDAPSE (Drug) $1,772
- AUBAGIO (Drug) $996.33
- BIOMONITOR (Device) $939.59
- Aimovig (Biological) $714.84
- TYSABRI (Biological) $601.00
- OCREVUS (Biological) $521.58
- VYVGART (Drug) $490.92
- Briviact (Drug) $413.66
- VYEPTI (Biological) $374.97
- NAMZARIC (Drug) $326.80
- NORTHERA (Drug) $322.30
- LEMTRADA (Drug) $314.27
- SOLIRIS (Drug) $299.52
- ZINBRYTA (Biological) $275.00
- ZEPOSIA (Drug) $249.46
- KESIMPTA (Drug) $231.47
- AIMOVIG (Biological) $222.19
- NUEDEXTA (Drug) $219.55
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Boca Raton
Dr. Hilton Becker, M.d, M.D
Specialist — Payments: $666,268
Specialist $666,268
Dr. Raul Carballosa, M.d, M.D
Specialist — Payments: $392,097
Specialist $392,097
David Levenson, M.d, M.D
Specialist — Payments: $112,013
Specialist $112,013
Dr. Gregory Albert, M.d, M.D
Specialist — Payments: $79,857
Specialist $79,857
Dr. Rolando Rodriguez, M.d, M.D
Specialist — Payments: $79,116
Specialist $79,116
Mrs. Cristina Keusch, M.d, M.D
Specialist — Payments: $67,026
Specialist $67,026